Heat Biologics is a clinical-stage company focused on developing its novel off-the-shelf ImPACT therapeutic vaccines to combat a wide range of cancers and infectious diseases. ImPACT Therapy exploits the natural ability of antigens to activate the immune system by utilizing live, irradiated, off-the-shelf, genetically modified cells injected into a patient designed to elicit a powerful immune response against the disease target. Heat’s ImPACT Therapy is based upon heat shock protein gp-96, a chaperone protein found in all human cells and normally tethered to our cells with a leash called the KDEL sequence. ImPACT Therapy removes this KDEL leash, thus transforming allogeneic living cells into powerful miniature osmotic pumps that continually secrete gp96 and their chaperoned antigens to activate the immune system against the full spectrum of antigens expressed by a patient’s disease. Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).
View our latest Corporate PresentationView Presentation